Authors

Latest:

Dr. Carlson on Treating Breast Cancer Patients Under 40

Grant W. Carlson, MD, professor of surgery, Emory University School of Medicine, chief, Division of Plastic Surgery, Emory University Hospital, discusses treating younger patients with breast cancer.

Greg Kennelty

Latest:

Individualized Treatment Needed for Patients With NRAS-Mutated mCRC

Activating, hotspot mutations in the NRAS gene occur in a small subset of patients with metastatic colorectal cancer. These mutations are now being identified in routine clinical practice by extended RAS genotyping.

Greg Riedlinger, MD, PhD, Rutgers University

Gregory A. Daniels, MD, PhD

Latest:

Dr. Daniels on Immunotherapy in Head and Neck Cancer

Gregory A. Daniels, MD, PhD, medical oncologist, associate professor of medicine, UC San Diego Health, discusses the role of immunotherapy for patients with head and neck cancer.

Gregory A. Grabowski, MD

Latest:

Dr. Grabowski Explains the Effects of Enzyme Therapy

Dr. Gregory A. Grabowski from Cincinnati Children's Hospital Medical Center Explains the Effects of Enzyme Therapy

Gregory A. Otterson, MD

Latest:

Dr. Otterson on the Utility of Immunotherapy in NSCLC

Gregory A. Otterson, MD, discusses data examining immunotherapy alone versus in combination in non–small cell lung cancer.

Gregory E. Idos, MD

Latest:

Dr. Idos on Remaining Questions With Multiplex Panel Testing

Gregory E. Idos, MD, assistant professor of Clinical Medicine, Department of Surgery, Division of Colorectal Surgery, Keck School of Medicine of University of Southern California, sheds light on the remaining questions with multiplex panel testing as well as the cost effectiveness of it.

Gregory J. Riely, MD, Memorial Sloan Kettering

Gregory J. Riely, MD PhD, Memorial Sloan Kettering Cancer Center

Gregory J. Riely, MD, PhD, Weill Cornell Medical College

Gregory L. Beatty, MD, PhD

Latest:

Dr. Beatty on the Potential for Immunotherapy in GI Malignancies

Gregory L. Beatty, MD, PhD, assistant professor of medicine, director of Tanslation Research, Pancreatic Cancer Research Center, University of Pennsylvania Perelman School of Medicine, discusses the potential for immunotherapy in gastrointestinal malignancies.

Gregory M. Springett, MD, PhD

Latest:

Immunotherapy Combined With Chemotherapy for Pancreatic Cancer: A Game Changer?

This article reviews up-to-date clinical studies combining chemotherapy with immunotherapy; it also explains the rationale for this combination in treatment of pancreatic cancer.

Gregory Riely, MD

Latest:

Experts Discuss How to Address Cardiac-Related Toxicities With EGFR TKIs

Gregory Riely, MD, and Shirish Gadgeel, MD, discuss how to address cardiac-related toxicities associated with treatment with EGFR TKIs.

Gregory Springett MD PhD

Latest:

Phase II Clinical Trial of Intratumoral Dendritic Cells Injections and Neoadjuvant Radiotherapy in Resectable Soft Tissue Sarcomas

Neoadjuvant radiation with dendritic cell injections has the potential to be safe, effective, and immunogenic in high-grade soft tissue sarcoma and needs to be confirmed in randomized larger clinical trials.

Gregory Vidal, MD, PhD

Latest:

Looking Towards The Future of HR+/HER2- Breast Cancer

The expert panel discusses ongoing research and offers closing thoughts on the future of HR+/HER2- breast cancer treatment.

Gregory W. Randolph, MD

Latest:

Dr. Randolph on Future Treatment Approaches in Thyroid Cancer

Gregory W. Randolph, MD, director, General and Thyroid Surgical Services, Massachusetts General Hospital, discusses the future methods of treating patients with thyroid cancer.

Gregory Zagaja, MD

Latest:

Dr. Zagaja on Major Benefit With Prostatectomy

Gregory Zagaja, MD, professor of Surgery, director of the Prostate Cancer Center at the University of Chicago Medicine, discusses the benefits of radical prostatectomy for patients with prostate cancer. Zagaja shared this insight during an interview at the 2016 OncLive State of the Science Summit on GU and Prostate Cancer.

Grzegorz S. Nowakowski, MD

Latest:

Other Key Follicular Lymphoma Data From ASH 2024

Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss follicular lymphoma data from ASH 2024.

Grzegorz S. Nowakowski, MD, Mayo Clinic

Latest:

Five-year Efficacy and Safety of Tafasitamab in Patients With Relapsed or Refractory DLBCL: Final Results From the Phase II L-MIND Study

Expert hematologist-oncologist Grzegorz Nowakowski, MD, reviews data from the 5-year analysis of the L-MIND study combining tafasitamab with lenalidomide in relapsed/refractory diffuse large B-cell lymphoma.

Guillem Argiles, MD

Latest:

Dr. Argiles Discusses the Role of Immunotherapy in CRC

Guillem Argiles, MD, staff member, Gastrointestinal Malignancies Division, Vall d’Hebron University Hospital, discusses the role of immunotherapy in colorectal cancer.